Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1Phase 1 1

Status

Recruiting 2Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Plasma cell 1Lymphoid 1

Conditions

Cholangiocarcinoma 2Neoplasm Metastasis 1Biliary Tract Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 56Specimen Handling 51Oxaliplatin 49Leucovorin 46Magnetic Resonance Spectroscopy 45Bevacizumab 43Gemcitabine 39Irinotecan 30Cetuximab 27Nivolumab 25130-nm albumin-bound paclitaxel 25Cisplatin 24Biopsy 24pembrolizumab 22Paclitaxel 22Capecitabine 19atezolizumab 18durvalumab 14Taxes 14Folfox protocol 14Carboplatin 13X-Rays 12Radiotherapy 12Cyclophosphamide 12fludarabine 11dehydroftorafur 10Radiation 10Albumin-Bound Paclitaxel 10Surgical Procedures, Operative 9Immunoglobulin G 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
futibatinib × Gastrointestinal × 30 days × Clear all
NCT05727176 2026-05-28

FOENIX-CCA4

Taiho Oncology, Inc.

Phase 2 Recruiting
120 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT06506955 2026-05-28

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Taiho Oncology, Inc.

Phase 2/3 Enrolling by invitation
15 enrolled
Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT05615818 2026-05-19

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting
800 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT07594548 2026-05-18

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Northwestern University

Phase 1 Not yet recruiting
18 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡